CA2999792A1 - Use of human derived immunosuppressive proteins and peptides as medicaments - Google Patents

Use of human derived immunosuppressive proteins and peptides as medicaments Download PDF

Info

Publication number
CA2999792A1
CA2999792A1 CA2999792A CA2999792A CA2999792A1 CA 2999792 A1 CA2999792 A1 CA 2999792A1 CA 2999792 A CA2999792 A CA 2999792A CA 2999792 A CA2999792 A CA 2999792A CA 2999792 A1 CA2999792 A1 CA 2999792A1
Authority
CA
Canada
Prior art keywords
amino acids
preferred
seq
polypeptide
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2999792A
Other languages
English (en)
French (fr)
Inventor
Magdalena Janina LASKA
Anne Margrethe TROLDBORG
Kristian Stengaard-Pedersen
Shervin Bahrami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aimvion AS
Original Assignee
Aimvion AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimvion AS filed Critical Aimvion AS
Publication of CA2999792A1 publication Critical patent/CA2999792A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2999792A 2015-10-01 2016-09-30 Use of human derived immunosuppressive proteins and peptides as medicaments Abandoned CA2999792A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201570620 2015-10-01
DKPA201570620 2015-10-01
DKPA201670634 2016-08-23
DKPA201670634 2016-08-23
PCT/DK2016/050316 WO2017054831A1 (en) 2015-10-01 2016-09-30 Use of human derived immunosuppressive proteins and peptides as medicaments

Publications (1)

Publication Number Publication Date
CA2999792A1 true CA2999792A1 (en) 2017-04-06

Family

ID=57144698

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2999792A Abandoned CA2999792A1 (en) 2015-10-01 2016-09-30 Use of human derived immunosuppressive proteins and peptides as medicaments

Country Status (6)

Country Link
US (1) US20190040106A1 (enExample)
EP (1) EP3356389A1 (enExample)
JP (1) JP7037486B2 (enExample)
CN (1) CN108368155A (enExample)
CA (1) CA2999792A1 (enExample)
WO (1) WO2017054831A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528071A (ja) * 2016-08-23 2019-10-10 エイムヴィオン・アクティエセルスカブＡｉｍＶｉｏｎ Ａ／Ｓ 新規免疫刺激ペプチド
JP7277466B2 (ja) * 2017-09-01 2023-05-19 インプラザー エー・ペー・エス 疾患の予防および／または治療における使用のためのワクチン
US11352421B2 (en) 2018-12-11 2022-06-07 Rush University Medical Center Treatment for adverse immune reaction to metal implant debris

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048763A1 (en) * 2000-02-04 2002-04-25 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis
WO2004087748A1 (en) * 2003-04-04 2004-10-14 Centre National De La Recherche Scientifique Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same
WO2005095442A1 (en) * 2004-03-30 2005-10-13 Institut Gustave Roussy Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
WO2009106073A2 (en) * 2008-02-28 2009-09-03 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding

Also Published As

Publication number Publication date
JP2018533974A (ja) 2018-11-22
CN108368155A (zh) 2018-08-03
US20190040106A1 (en) 2019-02-07
JP7037486B2 (ja) 2022-03-16
EP3356389A1 (en) 2018-08-08
WO2017054831A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
CA2689296C (en) Polypeptide inhibitors of hsp27 kinase and uses therefor
US7718610B2 (en) Retrocyclins: antiviral and antimicrobial peptides
EP2013232B1 (fr) Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer ou de l'inflammation
JP2022545554A (ja) Ｑ－ｅｒペプチド
WO2022029231A1 (en) Soluble npy2 receptor agonists
US20190040106A1 (en) Use of human derived immunosuppressive proteins and peptides as medicaments
WO2008083169A2 (en) Compositions and methods for the treatment of immunologic disorders
WO2021094259A1 (en) Npy2 receptor agonists
JP2018500272A (ja) 安定化アドレノメデュリン誘導体およびその使用
JP6357470B2 (ja) 改良されたｃｄ３１ペプチド
US20140288010A1 (en) Compositions and Methods for Increasing Stem Cell Survival
US11571455B2 (en) Methods and compositions for treating alcoholic liver disease
EP2983706B1 (en) Use of immune suppressive domains as medicaments
TR201807891T4 (tr) Fibroz ve karaciğer hastalıklarının tedavi edilmesi.
JP5769420B2 (ja) Ｎｃａｍ由来の新規ペプチド（ｆｇｌｓ）
JP6143270B2 (ja) マイオスタチン阻害ペプチド
WO2021243148A2 (en) Methods and compositions for treating alcoholic liver disease
ES2375601T3 (es) Lucha contra infecciones por virus de ih con plasma sangu�?neo humano oxidado con �?cido hipocloroso.
EP3333176A1 (en) Peptidic protein kinase c inhibitors and uses thereof
WO2019175869A1 (en) Treatment of a heart disease
CN106103467B (zh) 与细胞膜神经节苷脂相互作用的嵌合肽
TWI658832B (zh) 用於抑制骨髓衍生抑制細胞之組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210928

EEER Examination request

Effective date: 20210928

EEER Examination request

Effective date: 20210928

FZDE Discontinued

Effective date: 20240403